Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Prognostic factors of long-term outcome in surgically resectable pancreatic neuroendocrine tumors: A 12-year experience from a single center.

Zhou B, Duan J, Yan S, Zhou J, Zheng S.

Oncol Lett. 2017 Mar;13(3):1157-1164. doi: 10.3892/ol.2017.5561. Epub 2017 Jan 2.

2.

Pancreatic neuroendocrine tumors.

Sun J.

Intractable Rare Dis Res. 2017 Feb;6(1):21-28. doi: 10.5582/irdr.2017.01007. Review.

3.

Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.

Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, Kim MJ, Hwang DW, Meeker AK, Yu E, Kim SC, Hruban RH, Heaphy CM, Hong SM.

Clin Cancer Res. 2017 Mar 15;23(6):1598-1606. doi: 10.1158/1078-0432.CCR-16-1147. Epub 2016 Sep 23.

PMID:
27663587
4.

Irreversible electroporation for the treatment of pancreatic neuroendocrine tumors.

Papamichail M, Ali A, Pizanias M, Peddu P, Karani J, Heaton N.

Korean J Hepatobiliary Pancreat Surg. 2016 Aug;20(3):116-20. doi: 10.14701/kjhbps.2016.20.3.116. Epub 2016 Aug 29.

5.

Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience.

Shen C, Chen H, Chen H, Yin Y, Han L, Chen J, Tang S, Yin X, Zhou Z, Zhang B, Chen Z.

BMC Gastroenterol. 2016 Sep 9;16:111. doi: 10.1186/s12876-016-0505-5.

6.

Pancreatic Aetiology for Massive Upper Gastrointestinal Haemorrhage in Pregnancy.

Zaborowski A, Walsh SM, Ravi N, Reynolds JV.

Case Rep Surg. 2016;2016:5491851. doi: 10.1155/2016/5491851. Epub 2016 Feb 29.

7.

Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas.

Folkert IW, Hernandez P, Roses RE.

World J Gastroenterol. 2016 Mar 21;22(11):3105-16. doi: 10.3748/wjg.v22.i11.3105. Review.

8.

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review.

Ilett EE, Langer SW, Olsen IH, Federspiel B, Kjær A, Knigge U.

Diagnostics (Basel). 2015 Apr 8;5(2):119-76. doi: 10.3390/diagnostics5020119. Review.

9.

Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors.

Jiang Y, Jin JB, Zhan Q, Deng XX, Shen BY.

Chin Med J (Engl). 2015 Dec 20;128(24):3335-44. doi: 10.4103/0366-6999.171427.

10.

Postoperative Complications, In-Hospital Mortality and 5-Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review.

Jilesen AP, van Eijck CH, in't Hof KH, van Dieren S, Gouma DJ, van Dijkum EJ.

World J Surg. 2016 Mar;40(3):729-48. doi: 10.1007/s00268-015-3328-6. Review.

11.

Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems.

Yang M, Ke NW, Zeng L, Zhang Y, Tan CL, Zhang H, Mai G, Tian BL, Liu XB.

Medicine (Baltimore). 2015 Dec;94(48):e2156. doi: 10.1097/MD.0000000000002156. Erratum in: Medicine (Baltimore). 2016 Feb;95(6):e507d.

12.

Overestimated Oncologic Significance of Lymph Node Metastasis in G1 Nonfunctioning Neuroendocrine Tumor in the Left Side of the Pancreas.

Yoo YJ, Yang SJ, Hwang HK, Kang CM, Kim H, Lee WJ.

Medicine (Baltimore). 2015 Sep;94(36):e1404. doi: 10.1097/MD.0000000000001404.

13.

Behavior of Small, Asymptomatic, Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PNETs).

Jung JG, Lee KT, Woo YS, Lee JK, Lee KH, Jang KT, Rhee JC.

Medicine (Baltimore). 2015 Jul;94(26):e983. doi: 10.1097/MD.0000000000000983.

14.

Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification.

Brunner SM, Weber F, Werner JM, Agha A, Farkas SA, Schlitt HJ, Hornung M.

BMC Surg. 2015 Apr 25;15:49. doi: 10.1186/s12893-015-0033-1.

15.

Impact Total Psoas Volume on Short- and Long-Term Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcopenia.

Amini N, Spolverato G, Gupta R, Margonis GA, Kim Y, Wagner D, Rezaee N, Weiss MJ, Wolfgang CL, Makary MM, Kamel IR, Pawlik TM.

J Gastrointest Surg. 2015 Sep;19(9):1593-602. doi: 10.1007/s11605-015-2835-y. Epub 2015 Apr 30. Erratum in: J Gastrointest Surg. 2016 May;20(5):1082.

16.

Distal pancreatic resection for neuroendocrine tumors: is laparoscopic really better than open?

Xourafas D, Tavakkoli A, Clancy TE, Ashley SW.

J Gastrointest Surg. 2015 May;19(5):831-40. doi: 10.1007/s11605-015-2788-1. Epub 2015 Mar 11.

17.

Clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumors.

Furukori M, Imai K, Karasaki H, Watanabe K, Oikawa K, Miyokawa N, Taniguchi M, Furukawa H.

World J Gastroenterol. 2014 Dec 21;20(47):17949-54. doi: 10.3748/wjg.v20.i47.17949.

18.

Update on surgical treatment of pancreatic neuroendocrine neoplasms.

D'Haese JG, Tosolini C, Ceyhan GO, Kong B, Esposito I, Michalski CW, Kleeff J.

World J Gastroenterol. 2014 Oct 14;20(38):13893-8. doi: 10.3748/wjg.v20.i38.13893. Review.

19.

MicroRNA-218 inhibits cell invasion and migration of pancreatic cancer via regulating ROBO1.

He H, Hao SJ, Yao L, Yang F, Di Y, Li J, Jiang YJ, Jin C, Fu DL.

Cancer Biol Ther. 2014 Oct;15(10):1333-9. doi: 10.4161/cbt.29706. Epub 2014 Jul 10.

20.

Supplemental Content

Support Center